<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03896464</url>
  </required_header>
  <id_info>
    <org_study_id>SQuASH</org_study_id>
    <nct_id>NCT03896464</nct_id>
  </id_info>
  <brief_title>Soft-tissue Quadriceps Autograft ACL-reconstruction in the Skeletally-immature vs. Hamstrings</brief_title>
  <acronym>SQuASH</acronym>
  <official_title>Soft-tissue Quadriceps Autograft ACL-reconstruction in the Skeletally-immature vs. Hamstrings (SQuASH): A Multi-Centre Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Orthopaedic Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date, the use of the quadriceps tendon as an autograft option in primary paediatric
      Anterior Cruciate Ligament (ACL) reconstruction has not been well studied. The 2018
      International Olympic Committee (IOC) Consensus Statement now outlines the quadriceps tendon
      as a possible autograft option. However, no Randomised Control Trial (RCT) has examined the
      efficacy of the quadriceps tendon autograft in primary paediatric ACL reconstruction compared
      to the historical &quot;gold-standard&quot; soft-tissue hamstring autograft in this population. In
      light of its evidence for favourable outcomes in the adult population, and the (albeit
      limited) evidence showing safety and promise in the paediatric population, clinical equipoise
      exists for assessing its impact on outcomes in paediatric patients at the index surgery. This
      trial aims to demonstrate feasibility of a global RCT that will evaluate the efficacy of
      soft-tissue quadriceps versus hamstring autograft tendons on re-operation, return to sport,
      and knee function among paediatric patients undergoing primary ACL reconstruction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Autograft donation incisions will be covered with adhesive bandages for clinical outcome assessment by the attending physician. The assessor will perform a physical assessment of the patient's knees, including range of motion and laxity.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of reoperation</measure>
    <time_frame>2 years</time_frame>
    <description>Re-operation is defined as a composite of: failure (defined by one or more of: revision ACL surgery, MRI confirmation of re-rupture, Lachman 2+ and/or instrumented laxity measurement greater than 5 mm side-to-side difference), and non-failure indications (such as: meniscal tears requiring repair or menisectomy; osteochondral defects; symptomatic loose bodies; arthrofibrosis requiring manipulation under anesthesia and/or arthroscopic/open lysis of adhesions; removal of hardware; deep infection; and/or arthroscopic/open lavage without infection).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Return to Sport</measure>
    <time_frame>2 years</time_frame>
    <description>Return to sport (at any level and to pre-injury level) will be evaluated using the Tegner Activity Scale. The Tegner activity level scale is a graduated list of activities of daily living, recreation, and competitive sports, in which the response is presented as an 11-point Likert scale, where 0 indicates the lowest level of ability to perform work and sport functions, and 10 indicates competitive participation in high level sports.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Knee Function</measure>
    <time_frame>2 years</time_frame>
    <description>Patient Knee Function will be evaluated using the Pediatric International Knee Documentation Committee Subjective Form (Pedi-IKDC). The Pedi-IKDC is a 15 question form that consists of measures of daily living and sport activity, in which the response options are presented as either 4 or 10 point Likert scales. Scores for the form range from 0 (lowest level of function) to 100 (highest level of function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>2 years</time_frame>
    <description>Knee range of motion and both anterior and posterior and rotational stability will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of distal femoral and/or proximal tibial/fibular physeal injury</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of these injuries will be confirmed through standing hip-to-ankle plain radiographs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior Cruciate Ligament Integrity</measure>
    <time_frame>2 years</time_frame>
    <description>The Lachman test will be used to evaluate single and sagittal plane instability to determine integrity of the anterior cruciate ligament.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterolateral Rotary Instability of the Knee</measure>
    <time_frame>2 years</time_frame>
    <description>The pivot shift test will be used to detect anterolateral rotary instability of the knee</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ACL - Anterior Cruciate Ligament Rupture</condition>
  <arm_group>
    <arm_group_label>Soft-tissue hamstring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients in the study will undergo arthroscopic-assisted, single-bundle, complete transphyseal, anatomic primary ACL reconstruction at the discretion of the surgeon, considering the individual patient's age, physeal status, and anticipated years of growth remaining to skeletal maturity. Patients in this arm will undergo soft-tissue autograft reconstruction using hamstrings (i.e. semitendinosus and/or gracilis) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadriceps tendon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will undergo soft-tissue autograft reconstruction using all-soft-tissue quadriceps (i.e. full or partial thickness) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Soft tissue hamstring autograft</intervention_name>
    <description>Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.</description>
    <arm_group_label>Soft-tissue hamstring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quadriceps tendon autograft</intervention_name>
    <description>Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.</description>
    <arm_group_label>Quadriceps tendon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females aged 10-18 years.

          2. History, physical exam, and magnetic resonance imaging (MRI) or arthroscopic image
             confirmation of ACL insufficiency.

          3. Suitable for anatomic, single-bundle arthroscopic-assisted ACL reconstruction.

          4. Complete or partial transphyseal ACL femoral and tibial tunnel drilling/reconstruction
             techniques.

          5. Patient involved in sport (competitive and/or recreational level) prior to injury.

          6. Patient and parent/guardian speak, read, and understand the language of the clinical
             site.

          7. Patient and parent/guardian provide informed consent.

        Exclusion Criteria:

          1. Evidence (i.e. radiographic and/or arthroscopic) of International Cartilage Repair
             Society (ICRS) Cartilage Lesion Classification System Grade 2 and higher
             osteoarthritis.

          2. Tibial eminemence/spine fractures.

          3. Concomitant collateral, posterior cruciate, and/or cartilage pathology.

          4. Previous knee surgery in the affected or contra-lateral knee.

          5. Previous distal femur and/or proximal tibial/fibular physeal injury in the affected or
             contra-lateral knee.

          6. Allograft or allograft-augmentation of the ACL reconstruction.

          7. ACL reconstruction utilizing synthetic grafts.

          8. Primary ACL repair.

          9. Generalized ligamentous laxity and/or hypermobility (i.e. Beighton Criteria ≥ 4/9),
             given statistically significant higher failure rates (24% vs. 7.7%) and inferior
             subjective outcomes in this population.

         10. Significant medical co-morbidities (requiring daily assistance for activities of daily
             living).

         11. Patient, parent/guardian, and/or clinical investigator believe the patient will have
             difficulty maintaining follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darren de SA, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Darren de SA, MD, FRCSC</last_name>
    <phone>9059232126</phone>
    <email>darren.desa@medportal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Simunovic, MSc</last_name>
    <phone>(289) 237-3224</phone>
    <email>simunon@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren de SA, MSc</last_name>
      <email>darren.desa@medportal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Simunovic, MSc</last_name>
      <phone>(289) 237-3224</phone>
      <email>simunon@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Darren de SA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olufemi R Ayeni, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Devin C Peterson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debra Bartley, MD</last_name>
    </contact>
    <investigator>
      <last_name>Debra Bartley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sasha Carsen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sasha Carsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autograft</keyword>
  <keyword>Soft-tissue hamstring</keyword>
  <keyword>Quadriceps Tendon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

